Ibere Pharmaceuticals Watch

from 8-K 6 pages Sponsor Warrants Purchase Agreement

from 8-K 3 pages Pipv Capital LLC 2005 Market Street, Suite 2030 Philadelphia, Pa 19103 Re: Administrative Services Agreement Ladies and Gentlemen

from 8-K 19 pages Registration Rights Agreement

from 8-K 14 pages Investment Management Trust Agreement

from 8-K 6 pages Ibere Pharmaceuticals 2005 Market Street, Suite 2030 Philadelphia, Pa 19103 Re: Initial Public Offering Ladies and Gentlemen

from S-1 3 pages Pipv Capital LLC 2005 Market Street, Suite 2030 Philadelphia, Pa 19103 Re: Administrative Services Agreement Ladies and Gentlemen

from S-1 22 pages This Indemnity Agreement (This “Agreement”) Is Made as of [ ], 2021. Between: (1) Ibere Pharmaceuticals, an Exempted Company Incorporated Under the Laws of the Cayman Islands With Registered Office at 190 Elgin Avenue, George Town, Grand Cayman Ky1-9008, Cayman Islands (The “Company”); and (2) [ ] (“Indemnitee”). Whereas

from S-1 8 pages Sponsor Warrants Purchase Agreement

from S-1 10 pages Ibere Pharmaceuticals, a Cayman Islands Exempted Company (The “Company”), Is Pleased to Accept the Offer Pipv Capital LLC, a Delaware Limited Liability Company (The “Subscriber” or “You”), Has Made to Subscribe for 2,875,000 of the Company’s Class B Ordinary Shares (The “Shares”), US $0.0001 Par Value Per Share (The “Class B Shares”), Up to 375,000 of Which Are Subject to Forfeiture by You if the Underwriters of the Company’s Initial Public Offering of Its Securities (“Ipo”), if Any, Do Not Fully Exercise Their Overallotment Option (The “Overallotment Option”). for the Purposes of This Agreement (This “Agreement”), References to “Ordinary Shares” Are To, Collectively, the Class B Shares and the Company’s Class a Ordinary Shares, US $0.0001 Par Value Per Share (The “Class a Shares”). Upon Certain Terms and Conditions, the Class B Shares Will Automatically Convert Into Class a Shares on a One-For-One Basis, Subject to Adjustment. Unless the Context Otherwise Requires, as Used Herein “Shares” Shall Be Deemed to Include Any Class a Shares Issued Upon Conversion of the Class B Shares Comprising the Shares. the Terms on Which the Company Is Willing to Issue the Shares to the Subscriber, and the Company and the Subscriber’s Agreements Regarding Such Shares, Are as Follows: 1. Subscription of Shares

from S-1 22 pages Registration Rights Agreement

from S-1 16 pages Investment Management Trust Agreement

from S-1 5 pages Promissory Note

from S-1 6 pages Ibere Pharmaceuticals 2005 Market Street, Suite 2030 Philadelphia, Pa 19103 Re: Initial Public Offering Ladies and Gentlemen

from DRS 10 pages Ibere Pharmaceuticals, a Cayman Islands Exempted Company (The “Company”), Is Pleased to Accept the Offer Pipv Capital LLC, a Delaware Limited Liability Company (The “Subscriber” or “You”), Has Made to Subscribe for 2,875,000 of the Company’s Class B Ordinary Shares (The “Shares”), US $0.0001 Par Value Per Share (The “Class B Shares”), Up to 375,000 of Which Are Subject to Forfeiture by You if the Underwriters of the Company’s Initial Public Offering of Its Securities (“Ipo”), if Any, Do Not Fully Exercise Their Overallotment Option (The “Overallotment Option”). for the Purposes of This Agreement (This “Agreement”), References to “Ordinary Shares” Are To, Collectively, the Class B Shares and the Company’s Class a Ordinary Shares, US $0.0001 Par Value Per Share (The “Class a Shares”). Upon Certain Terms and Conditions, the Class B Shares Will Automatically Convert Into Class a Shares on a One-For-One Basis, Subject to Adjustment. Unless the Context Otherwise Requires, as Used Herein “Shares” Shall Be Deemed to Include Any Class a Shares Issued Upon Conversion of the Class B Shares Comprising the Shares. the Terms on Which the Company Is Willing to Issue the Shares to the Subscriber, and the Company and the Subscriber’s Agreements Regarding Such Shares, Are as Follows: 1. Subscription of Shares

from DRS 5 pages Promissory Note